Objectives Patients with SLE take multiple medications. Within a large prospective longitudinal SLE cohort, we characterised ...

Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company with a market capitalization of $156.6 million, is at a pivotal juncture in its development of programmed cellular ...

Similarly, CLN-978 is a first-in-class T-cell engager targeting SLE and RA. It can also potentially ... Zipalertinib is also in Phase 3. Note that the FDA has granted CLN-081 the Breakthrough ...

Operator Welcome to the Bristol Myers Squibb fourth quarter 2024 earnings conference call. [Operator instructions] Please note this event is being recorded. I would now like to turn the conference ...

Comparison of that ancient DNA with modern human DNA showed that the two species had interbred and that people today still ...

The most common type of lupus, systemic lupus erythematosus, has previously been associated with an increased risk of heart disease, researchers said in background notes. But it’s not been clear ...

Of note, ORR hit 100% in patients who had undergone prior ... companies are trialing for immune-mediated conditions such as multiple sclerosis and systemic lupus erythematosus. Tuesday’s acquisition ...

Genetically predicted rheumatoid arthritis (RA) is causally associated with prostate cancer (PCa), according to a study ...

Patients with SLE vs individuals without autoimmune disease demonstrated higher rates of peripartum complications.

Systemic lupus erythematosus, more commonly known as lupus, has a variety of symptoms and room for improvement when it comes ...

A significant association was found between dementia duration and emergency department use among older adults with systemic lupus erythematosus.

EULAR/ACR SLE classification criteria were not linked to mortality or hospitalization, a developed ominosity model adequately predicted mortality.